This report provides a preview of clinical trials that are planned to be initiated and projected to be completed in 2025.
Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
Scope
- This report provides an overview of clinical trials that are planned to be initiated and projected to be completed in 2025 captured in the the analyst Pharma Intelligence Center until December 19, 2024. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
Reasons to Buy
- See a preview of the clinical trials that are planned to be initiated and those projected to be completed in 2025.
- Identify key analysis and segmentation of these trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use.
Table of Contents
- 1.Tables and Figures
- 2.Executive Summary
- 3.Introduction
- 4.Clinical Trials Planned to Initiate 2025
- 5.Clinical Trials Estimated to Complete in 2025
- 6.Key Findings
- 7.Appendix
Figures 1 and 2: Planned clinical trials, by phase and sponsor type
Figure 3: Planned clinical trials, top industry sponsors, by phase
Figure 4: Planned clinical trials, top non-industry sponsors, by phase
Figure 5: Planned clinical trials, single-country or multinational, by sponsor type and phase
Figure 6: Planned clinical trials, regions, by phase
Figure 7: Planned clinical trials, regions, by phase and distribution
Figure 8: Planned clinical trials, country, by phase
Figure 9: Planned clinical trials, country, by phase and distribution
Figures 10 and 11: Planned clinical trials, drug type, by phase and distribution
Figure 12: Planned clinical trials, top therapy areas, by phase
Figure 13: Planned clinical trials, top therapy areas, by phase and distribution
Figure 14: Planned clinical trials, top indications, by phase
Figure 15: Planned clinical trials, top indications, by phase and distribution
Figures 16 and 17: Total planned DCTs, by therapeutic area
Figure 18: Clinical trials estimated to complete, by phase
Figures 19 and 20: Clinical trials estimated to complete, by status and phase distribution
Figure 21: Clinical trials estimated to complete, by sponsor type and phase
Figure 22: Clinical trials estimated to complete, by top industry sponsor and phase
Figure 23: Clinical trials estimated to complete, by top non-industry sponsor and phase
Figure 24: Single-country or multinational clinical trials estimated to complete, by region
Figure 25: Clinical trials estimated to complete, by country
Figure 26: Clinical trials estimated to complete, by therapy area and phase
Figures 27 and 28: Total DCTs estimated to complete, by region and single-country or multinational
Figure 29: DCTs estimated to complete, by therapy area and phase
